BCAT1 and central nervous system cancer: The results showed that the overall survival (OS) time of glioma patients with higher BCAT1 expression (TCGA, IDH1WT:67.8%; CGGA, IDH1WT:74.5%) is shorter than patients with lower BCAT1 expression (TCGA, IDH1WT:5.9%; CGGA, IDH1WT:14.8%) (Figure 2A, 2D).